A critical review of microbiome-derived metabolic functions and translational research in liver diseases
Frontiers in Cellular and Infection Microbiology · 24.02.2025 · 15
DOI: 10.3389/fcimb.2025.1488874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 24.02.2025. Verfasst von Raja Ganesan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Tamil Nadu, India. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Translational Research, Biomedical, Liver Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Significant changes in gut microbial composition are associated with chronic liver disease. Using preclinical models, it has been demonstrated that ethanol/alcohol-induced liver disease is transmissible through fecal microbiota transplantation (FMT). So, the survival rate of people with severe alcoholic hepatitis got better, which suggests that changes in the makeup and function of gut microbiota play a role in metabolic liver disease. The leaky intestinal barrier plays a major role in influencing metabolic-related liver disease development through the gut microbiota. As a result, viable bacteria and microbial products can be transported to the liver, causing inflammation, contributing to hepatocyte death, and causing the fibrotic response. As metabolic-related liver disease starts and gets worse, gut dysbiosis is linked to changes in the immune system, the bile acid composition, and the metabolic function of the microbiota in the gut. Metabolic-related liver disease, as well as its self-perpetuation, will be demonstrated using data from preclinical and human studies. Further, we summarize how untargeted treatment approaches affect the gut microbiota in metabolic-related liver disease, including dietary changes, probiotics, antibiotics, and FMT. It discusses how targeted therapies can improve liver disease in various areas. These approaches may improve metabolic-related liver disease treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Tamil Nadu, India.
- Department of Bioscience, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.
- Institute for Liver and Digestive Disease, Hallym University, Chuncheon, Republic of Korea.
- Department of Microbiology, School of Basic Science, Central University of Punjab, Bathinda, Punjab, India.
- Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology, School of Health Sciences, Central University of Punjab, Bathinda, Punjab, India.
- Neurochemistry and Neuroendocrinology Lab, Department of Zoology, Central University of Punjab, Bathinda, Punjab, India.
Zitieren
APA
Ganesan, R., Thirumurugan, D., Vinayagam, S., Kim, D. J., Suk, K. T., Iyer, M., Yadav, M. K., HariKrishnaReddy, D., Parkash, J., Wander, A., & Vellingiri, B. (2025). A critical review of microbiome-derived metabolic functions and translational research in liver diseases. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1488874
Vancouver
Ganesan R, Thirumurugan D, Vinayagam S, Kim DJ, Suk KT, Iyer M, et al. A critical review of microbiome-derived metabolic functions and translational research in liver diseases. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1488874
BibTeX
@article{Ganesan2025,
author = {Ganesan, Raja and Thirumurugan, Durairaj and Vinayagam, Saranya and Kim, Dong Joon and Suk, Ki Tae and Iyer, Mahalaxmi and Yadav, Mukesh Kumar and HariKrishnaReddy, Dibbanti and Parkash, Jyoti and Wander, Arvinder and Vellingiri, Balachandar},
title = {A critical review of microbiome-derived metabolic functions and translational research in liver diseases},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1488874}
}
EUVIMED